Cargando…

Differential V2-directed antibody responses in non-human primates infected with SHIVs or immunized with diverse HIV vaccines

V2p and V2i antibodies (Abs) that are specific for epitopes in the V1V2 region of the HIV gp120 envelope (Env) do not effectively neutralize HIV but mediate Fc-dependent anti-viral activities that have been correlated with protection from, or control of HIV, SIV and SHIV infections. Here, we describ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Weiss, Svenja, Itri, Vincenza, Pan, Ruimin, Jiang, Xunqing, Luo, Christina C., Morris, Lynn, Malherbe, Delphine C., Barnette, Philip, Alexander, Jeff, Kong, Xiang-Peng, Haigwood, Nancy L., Hessell, Ann J., Duerr, Ralf, Zolla-Pazner, Susan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8850611/ https://www.ncbi.nlm.nih.gov/pubmed/35173151 http://dx.doi.org/10.1038/s41467-022-28450-1

Ejemplares similares

Vaccine-induced V1V2-specific antibodies control and or protect against infection with HIV, SIV and SHIV
por: Zolla-Pazner, Susan, et al.
Publicado: (2019)

Modified Adenovirus Prime-Protein Boost Clade C HIV Vaccine Strategy Results in Reduced Viral DNA in Blood and Tissues Following Tier 2 SHIV Challenge
por: Malherbe, Delphine C., et al.
Publicado: (2021)

Complement contributes to antibody-mediated protection against repeated SHIV challenge
por: Goldberg, Benjamin S., et al.
Publicado: (2023)

Modulation of Antibody Responses to the V1V2 and V3 Regions of HIV-1 Envelope by Immune Complex Vaccines
por: Hioe, Catarina E., et al.
Publicado: (2018)

Pre-existing neutralizing antibody mitigates B cell dysregulation and enhances the Env-specific antibody response in SHIV-infected rhesus macaques
por: Jaworski, Juan Pablo, et al.
Publicado: (2017)

Single-dose bNAb cocktail or abbreviated ART post-exposure regimens achieve tight SHIV control without adaptive immunity
por: Shapiro, Mariya B., et al.
Publicado: (2020)

Early short-term treatment with neutralizing human monoclonal antibodies halts SHIV infection in newborn macaques
por: Hessell, Ann J., et al.
Publicado: (2016)

Vaccination with immune complexes modulates the elicitation of functional antibodies against HIV-1
por: Hioe, Catarina E., et al.
Publicado: (2023)

Corrigendum: Vaccination with immune complexes modulates the elicitation of functional antibodies against HIV-1
por: Hioe, Catarina E., et al.
Publicado: (2023)

Advances in SIV/SHIV Non-Human Primate Models of NeuroAIDS
por: Moretti, Sonia, et al.
Publicado: (2021)

Optimized protocol for detection of native, full‐length HIV‐1 envelope on the surface of transfected cells
por: Altman, J.B., et al.
Publicado: (2018)

Evidence for the Role of a Second Fc-Binding Receptor in Placental IgG Transfer in Nonhuman Primates
por: Rosenberg, Yvonne J., et al.
Publicado: (2023)

Priming with DNA Expressing Trimeric HIV V1V2 Alters the Immune Hierarchy Favoring the Development of V2-Specific Antibodies in Rhesus Macaques
por: Devasundaram, Santhi, et al.
Publicado: (2020)

Native envelope-based immunogens derived from critical timepoints in the development of breadth elicit rapid neutralizing antibodies in rabbits
por: Malherbe, DC, et al.
Publicado: (2012)

Passive neutralizing antibody controls SHIV viremia and enhances B cell responses in infant macaques
por: Ng, Cherie T., et al.
Publicado: (2010)

Improved delivery of broadly neutralizing antibodies by nanocapsules suppresses SHIV infection in the CNS of infant rhesus macaques
por: Wen, Jing, et al.
Publicado: (2021)

Advancing HIV Broadly Neutralizing Antibodies: From Discovery to the Clinic
por: Spencer, David A., et al.
Publicado: (2021)

Evaluation of chimeric antigen receptor T cell therapy in non-human primates infected with SHIV or SIV
por: Iwamoto, Nami, et al.
Publicado: (2021)

The Critical Role of Nonhuman Primates in Medical Research
por: Friedman, Henry, et al.
Publicado: (2017)

Identifying epitopes of HIV-1 that induce protective antibodies
por: Zolla-Pazner, Susan
Publicado: (2004)

Rationally Targeted Mutations at the V1V2 Domain of the HIV-1 Envelope to Augment Virus Neutralization by Anti-V1V2 Monoclonal Antibodies
por: Shen, Guomiao, et al.
Publicado: (2015)

Efficacy of silk fibroin biomaterial vehicle for in vivo mucosal delivery of Griffithsin and protection against HIV and SHIV infection ex vivo
por: Crakes, Katti R, et al.
Publicado: (2020)

The Use of Nonhuman Primate Models in HIV Vaccine Development
por: Morgan, Cecilia, et al.
Publicado: (2008)

Functional Antibody Response Against V1V2 and V3 of HIV gp120 in the VAX003 and VAX004 Vaccine Trials
por: Balasubramanian, Preetha, et al.
Publicado: (2018)

Immune Correlates of Disease Progression in Linked HIV-1 Infection
por: Tuen, Michael, et al.
Publicado: (2019)

OA021-02. Replicating measles-SHIV vaccine induces long term preservation of central memory CD4 cells in the gut of vaccinated macaques challenged with SHIV
por: Tangy, F, et al.
Publicado: (2009)

Non-neutralizing IgG anti-PID antibodies decreased viral load following high dose vaginal challenge of non-human primates
por: Moog, C, et al.
Publicado: (2012)

Antibody-based CCR5 blockade protects Macaques from mucosal SHIV transmission
por: Chang, Xiao L., et al.
Publicado: (2021)

Rapid Induction of Multifunctional Antibodies in Rabbits and Macaques by Clade C HIV-1 CAP257 Envelopes Circulating During Epitope-Specific Neutralization Breadth Development
por: Malherbe, Delphine C., et al.
Publicado: (2020)

Phagocytosis by an HIV antibody is associated with reduced viremia irrespective of enhanced complement lysis
por: Spencer, David A., et al.
Publicado: (2022)

Broadly Neutralizing Human Anti-HIV Antibody 2G12 Is Effective in Protection against Mucosal SHIV Challenge Even at Low Serum Neutralizing Titers
por: Hessell, Ann J., et al.
Publicado: (2009)

P19-21. Sequence variability in the crown of the V3 loop of the HIV-1 envelope is clustered within a small 3D structural zone
por: Almond, D, et al.
Publicado: (2009)

HIV-1 Envelope Glycoprotein Resistance to Monoclonal Antibody 2G12 Is Subject-Specific and Context-Dependent in Macaques and Humans
por: Malherbe, Delphine C., et al.
Publicado: (2013)

CD4+ T Cells Are Dispensable for Induction of Broad Heterologous HIV Neutralizing Antibodies in Rhesus Macaques
por: Sarkar, Sanghita, et al.
Publicado: (2021)

Immunoprophylaxis against Mother-to-Child Transmission of HIV-1
por: Gorny, Miroslaw K, et al.
Publicado: (2006)

P20-09. Worldwide epitope prevalence of crystallographically resolved anti-V3 antibodies
por: Swetnam, J, et al.
Publicado: (2009)

Vaccine-Induced Protection from Homologous Tier 2 SHIV Challenge in Nonhuman Primates Depends on Serum-Neutralizing Antibody Titers
por: Pauthner, Matthias G., et al.
Publicado: (2019)

Human Anti-V3 HIV-1 Monoclonal Antibodies Encoded by the VH5-51/VL Lambda Genes Define a Conserved Antigenic Structure
por: Gorny, Miroslaw K., et al.
Publicado: (2011)

Crystal structure analysis of anti-V2 mAb 2158 suggests a conformational epitope involving an N-linked glycan
por: Spurrier, B, et al.
Publicado: (2012)

Biophysical dissection of the antigen-antibody interaction of the broadly reactive anti-V3 human mAb 447-52D
por: Killikelly, A, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_1pgbrvrbh1irvs3klmbk146uo3